PTC Therapeutics, Inc
PTC Therapeutics is a U.S.-based global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders. Its portfolio includes approved therapies and clinical-stage programs for neurology and metabolism, with commercialization across the United States, Europe, Latin America, and other international markets through direct operations and partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved therapies sold in the U.S., Europe, Latin America, and other territories.
Access programs used to supply medicines in markets without full commercial launch.
Collaborative revenue tied to partnered programs such as SMA-related agreements.
Research, discovery, and clinical-stage programs in neurology and metabolism.
Products
Reported · share of revenue- Collaboration and License Revenue54.6 %
- Royalty13.4 %
- Translarna112.9 %
- Emflaza8.0 %
- Sephience6.1 %
- Other5.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
PTC Therapeutics sells primarily to patients with rare diseases through specialty pharmacies, hospitals, distributors, and reimbursement systems rather than to mass-market consumers. The end payer is often a government health program or third-party insurer, so access depends on pricing, reimbursement, and regulatory authorization in each market.
Patients with DMD, PKU, AADC deficiency, hATTR amyloidosis, and FCS who receive treatment through prescribed specialty channels.
U.S. dispensing partners that receive prescriptions, manage fulfillment, and ship products directly to patients.
State programs and national health systems that reimburse high-cost orphan medicines and determine access.
Commercial and managed-care payers that cover specialty drugs and influence net realized pricing.
European and international channels that buy for reimbursed access, compassionate use, or early access programs.
Strategy
PTC Therapeutics is focused on expanding its rare-disease franchise by commercializing approved products and advancing a diversified pipeline in neurology and metabolism. It also uses partnerships, early-access channels, and global infrastructure to broaden patient access while pursuing new approvals and label opportunities.
Approved products generate the core revenue base and fund development.
Rare-disease drugs depend on payer approval and local distribution infrastructure.
Pipeline breadth supports future growth beyond current products.
Additional labels can extend product longevity and broaden addressable patients.
Geography
Q1/2026PTC Therapeutics operates globally, with commercial activity in the United States, the EEA, Latin America, and selected other territories. The company relies heavily on international markets for several products, while U.S. commercialization is important for Emflaza and Sephience and Europe is important for Translarna and Upstaza/Kebilidi.
Share of the revenue the company reports by geography.
Risks
PTC Therapeutics depends on maintaining marketing authorizations, reimbursement, and supply for a concentrated set of rare-disease products, so regulatory or payer setbacks can quickly affect revenue. Its international footprint also adds exposure to country-specific pricing, reimbursement, and order timing volatility, while pipeline development and financing needs create typical biotech execution risk.
- Marketing authorization renewal and compliance riskImpact: HighLikelihood: High
Several products depend on maintaining approvals and meeting local conditions.
Exposure - Reimbursement and pricing pressureImpact: HighLikelihood: High
Rare-disease medicines require payer coverage and acceptable pricing to drive uptake.
Exposure: U.S. specialty pharmacy sales and international market access
- International concentration and country-specific volatilityImpact: MediumLikelihood: High
A substantial portion of sales occurs outside the United States and can be uneven by quarter.
Exposure - Third-party manufacturing and supply chain dependenceImpact: MediumLikelihood: Medium
Commercial supply relies on external manufacturers and logistics partners.
Exposure - Clinical development and financing riskImpact: MediumLikelihood: Medium
Pipeline programs require successful trials and ongoing capital to advance.
Exposure
Accounting
Judgemental itemsRevenue is recognized net of estimated rebates, discounts, and allowances, which requires judgment.
Impact: Can materially change reported product sales and quarterly comparability
Named-patient and centralized purchases may cover multiple months of therapy.
Impact: Creates uneven revenue recognition across quarters
Collaborative revenue from partners such as Roche and others depends on contractual triggers.
Impact: Can create non-recurring or lumpy revenue streams
Interest expense includes convertible notes and royalty-related liabilities.
Impact: Affects financing costs and balance sheet presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Design Therapeutics, Inc.
DSGN · Pharmaceutical Preparations
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a small-molecule platform designed to target the underlying…
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Amicus Therapeutics, Inc.
Pharmaceutical Preparations
Travere Therapeutics, Inc.
TVTX · Pharmaceutical Preparations
Travere Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for rare diseases, with commercial products in kidney and metabolic disorders.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Last updated: 24/09/2026